Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients
暂无分享,去创建一个
M. Baccarani | M. Vignetti | G. Rosti | F. Cottone | F. Guilhot | F. Efficace | M. Breccia | L. Cannella
暂无分享,去创建一个
M. Baccarani | M. Vignetti | G. Rosti | F. Cottone | F. Guilhot | F. Efficace | M. Breccia | L. Cannella